Revenue (Annual)

Revenue: The sum of all revenue fields included for a company's operating activities.

IGC Pharma, Inc. (IGC) had Revenue of $1.27M for the most recently reported fiscal year, ending 2025-03-31.

Quarterly Annual

Figures for fiscal year ending 2025-03-31

Income Statement Financials
Revenue	$1.27M
Net Income	$-7.12M
Cost of Goods Sold	$0.65M
Gross Profit	$0.62M
Operating Expenses	$8.72M
Operating Income	$-7.45M
Non-Operating Income/Expense	$0.33M
Pre-Tax Income	$-7.12M
Normalized Pre-Tax Income	$-7.12M
Income after Taxes	$-7.12M
Income from Continuous Operations	$-7.12M
Consolidated Net Income/Loss	$-7.12M
Normalized Income after Taxes	$-7.12M
EBIT	$-7.45M
EBITDA	$-6.83M
Weighted-Average Shares Outstanding (Basic)	76.52M
Weighted-Average Shares Outstanding (Diluted)	76.52M
Earnings per Share (EPS) (Basic)	$-0.09
Earnings per Share (EPS) (Diluted)	$-0.09
Balance Sheet Financials
Current Assets	$2.90M
Property, Plant, and Equipment	$3.22M
Long-Term Assets	$5.85M
Total Assets	$8.75M
Current Liabilities	$2.26M
Long-Term Debt	$0.13M
Long-Term Liabilities	$0.16M
Total Liabilities	$2.42M
Common Equity	$6.33M
Tangible Shareholders Equity	$4.48M
Shareholders Equity	$6.33M
Common Shares Outstanding	80.88M
Cash Flow Statement Financials
Cash Flow from Operating Activities	$-4.79M
Cash Flow from Investing Activities	$-0.44M
Cash Flow from Financial Activities	$4.45M
Beginning Cash	$1.20M
End Cash	$0.41M
Increase/Decrease in Cash	$-0.79M
Stock-Based Compensation	$1.64M
Common Stock Dividends Paid	--
Preferred Stock Dividends Paid	--
Fundamental Metrics & Ratios
Current Ratio	1.28
Non-Performing Assets / Total Loans	--
Loan Loss Reserves / Non-Performing Loans	--
Debt to Capital Ratio	0.02
Debt to Equity Ratio	0.02
Gross Margin	48.70%
Operating Margin	-585.84%
EBIT Margin	-585.84%
EBITDA Margin	-537.21%
Pre-Tax Profit Margin	-560.27%
Profit Margin	-560.27%
Free Cash Flow	$-4.87M
Loss Ratio	--
Expense Ratio	--
Combined Ratio	--
Asset Turnover	0.15
Inventory Turnover	0.48
Receiveable Turnover	37.38
Days Sales in Receivables	9.76
Return on Equity	-112.50%
Return on Tangible Equity	-159.02%
Return on Assets	-81.41%
Return on Investments	-110.16%
Book Value Per Share	$0.08
Free Cash Flow per Share	$-0.06
Operating Cash Flow per Share	$-0.06

Data from Zacks Investment Research, Inc.